Author

Antonio Mulero-Sánchez

COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)
COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)

Antonio Mulero-Sánchez  et al.

Item 1 - 1 / 1
1